NCT00409357View on ClinicalTrials.gov

Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

473

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions
Benign Prostatic Hyperplasia
Interventions
DRUG

SL77.0499-10 (alfuzosin hydrochloride)

Trial Locations (1)

Unknown

Sanofi-Aventis, Tokyo

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00409357 - Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia | Biotech Hunter | Biotech Hunter